---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-026070"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2023-06-02T23:59:59+00:00"
generated_at: "2026-06-14T08:14:36.964157+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Xenon Pharmaceuticals announces results of 2023 annual meeting; all proposals approved

## Summary
- All 8 director nominees elected; highest vote count 50.7M (Svoronos, Gannon), lowest 48.5M (Machado).
- Say-on-pay advisory vote approved: 44.2M for, 6.7M against, 3.3K abstain; 1.9M broker non-votes.
- KPMG appointed as auditor with 51.5M votes for, 1.3M withheld.
- Auditor remuneration authority approved: 50.7M for, 284K against, 2.8K abstain; 1.8M broker non-votes.

## SEC filing metadata
- accession: 0000950170-23-026070
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2023-06-02T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000095017023026070/0000950170-23-026070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000095017023026070/xene-20230601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-026070
- JSON: https://secwatch.observer/filing/0000950170-23-026070.json
- Plain text: https://secwatch.observer/filing/0000950170-23-026070.txt

## Key facts
- Shareholder Votes
  Xenon Pharmaceuticals Inc. shareholders approved Remuneration of Auditor at the 2023-06-01 meeting.
  - Outcome: passed
  - Meeting: 2023-06-01
  source text: The authority of the audit committee of the Board to set the remuneration of the auditor for the ensuing year was approved as follows: For Against Abstain Broker Non-Votes 50,683,345 284,460 2,832 1,827,721
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582313/000095017023026070/0000950170-23-026070-index.htm
- Shareholder Votes
  Xenon Pharmaceuticals Inc. shareholders approved Election of Directors at the 2023-06-01 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-01
  source text: The following nominees were elected as directors to serve until the 2024 annual meeting of shareholders or until their respective successors are duly elected and qualified: For Against Broker Non-Votes Simon Pimstone 49,766,312 1,105,033 1,927,013 Dawn Svoronos 50,657,151 214,194 1,927,013 Mohammad Azab 49,442,996 1,428,349 1,927,013 Steven Gannon 50,683,492 187,853 1,927,013 Elizabeth Garofalo 50,657,402 213,943 1,927,013 Patrick Machado 48,515,986 2,355,359 1,927,013 Ian Mortimer 50,663,448 207,897 1,927,013 Gary Patou 48,629,611 2,241,734 1,927,013
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582313/000095017023026070/0000950170-23-026070-index.htm
- Shareholder Votes
  Xenon Pharmaceuticals Inc. shareholders approved Advisory Vote on Compensation of Named Executive Officers (Say-on-Pay) at the 2023-06-01 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-01
  source text: The compensation of the Company’s named executive officers, on an advisory basis, was approved as follows: For Against Abstain Broker Non-Votes 44,167,661 6,700,364 3,320 1,927,013
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582313/000095017023026070/0000950170-23-026070-index.htm
- Shareholder Votes
  Xenon Pharmaceuticals Inc. shareholders approved Appointment of Auditor at the 2023-06-01 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-01
  source text: The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the ensuing year was approved as follows: For Withheld Broker Non-Votes 51,532,487 1,265,871 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582313/000095017023026070/0000950170-23-026070-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.